Merck, Bayer’s heart failure therapy Verquvo now approved for use across Europe

WORLD – Verquvo, a drug developed for the treatment of symptomatic chronic heart failure has been cleared for use by the European Commission (EC). The approval reflects another important regulatory milestone in the development of the medicine which will provide doctors, health care professionals and patients with an important treatment option to complement currently available heart failure therapies. Merck and Bayer jointly co-developed Verquvo with Merck holding the commercial rights to the heart failure drug in the US and Bayer having exclusive commercial rights globally. The drug relayed successful data…

Read More

Merck setting ground on bioelectronic therapy under various partnerships with its latest involving Innervia Bioelectronics

EUROPE – Giant pharma company, Merck and Innervia Bioelectronics, a start-up and subsidiary of Inbrain Neuroelectronics have partnered to co-develop nex-gen smart neurostimulators for the treatment of severe chronic diseases, graphene-based bioelectronic vagus nerve therapies. Merck will leverage and build on its data science, clinical, regulatory and quality expertise as well as its bioelectronics research facilities while Innvervia will add its technical expertise in the development of graphene interfaces, device development and signal processing for clinical applications. Initially, the two companies will focus on inflammatory, metabolic and endocrine disorders by…

Read More

Merck Foundation provides scholarships to Mauritian doctors in commitment to build healthcare capacity

MAURITIUS – Merck Foundation, the philanthropic arm of Merck KGaA Germany, in partnership with Ministry of Health and Wellness, Mauritius, has underscored their commitment to build healthcare capacity through providing one-year PG Diploma and two-year Master Degree in many critical and underserved specialties for doctors from Mauritius. Senator, Dr. Rasha Kelej, CEO of Merck Foundation and President, Merck Foundation More Than a Mother explained, “I am very proud that in partnership with the Ministry of Health and Wellness of Mauritius, we have provided till today 71 scholarships of one-year diploma…

Read More

Merck and BioMedX set to partner as they strive to bolster their fight against cancer in a new joint cancer research programme

GERMANY – German based pharma company, Merck, and BioMed X, an independent research institute located at the University of Heidelberg in Germany have partnered to focus on their oncology related research. This is the eighth collaboration between the two organizations and is set to explore the role of extrachromosomal DNA (ecDNA) in cancer. BioMedX currently has two other ongoing oncology related programmes focused on DNA damage response and RNA splicing that this new research program is set to compliment. Extrachromosomal DNA (ecDNA) is any DNA that is found off the…

Read More

Michael Klobuchar appointed for newly created role of chief strategy officer at Merck

US – Michael Klobuchar has been appointed executive vice president and chief strategy officer of Merck as he will also become a member of Merck’s Executive Committee and lead the advancement and execution of the company’s strategy. At the time of his appointment, Klobuchar was senior vice president of Merck Research Laboratories Finance and Global Project and Alliance Management, he also previously served as the company’s senior vice president, Corporate Strategy and Financial Planning, and president, Merck Global Health Innovation Fund. Klobuchar has a Bachelor of Science degree in Chemical…

Read More

Sanofi’s and translate bio’s mRNA influenza vaccine now in its first phase clinical trials

US – Sanofi Pasteur, the vaccine global unit of Sanofi and Translate bio, is initiating the first phase clinical trials of its mRNA influenza vaccine. This is a move that proceeds positive preclinical safety and immunogenicity data of the mRNA vaccines which will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) vaccine candidate in up to 280 participants.  The development of this vaccine has been ongoing since a joint venture collaboration between Translate Bio and Sanofi Pasteur that involved an exclusive license agreement that has been ongoing…

Read More

Merck Foundation calls for action together with African First Ladies and Ministers to Build Healthcare Capacity

ZAMBIA – Merck foundation “More than a Mother” Ambassadors, African First Ladies of Angola, Botswana, Burkina Faso, Burundi, Central African Republic, Democratic Republic of Congo, Ghana, Guinea Conakry, Liberia, Malawi, Mozambique, and Namibia actively participated in the 8th edition of Merck Foundation Africa Asia Luminary which was co-chaired by Zambia First Lady, H.E. Esther Lungu and Merck Foundation CEO, Senator, Dr. Rasha Kelej. Merck Foundation, the philanthropic arm of Merck KgaA, conducted the 8th Edition of “Merck Foundation Africa Asia Luminary” 2021, through an online video conference. During the Luminary,…

Read More